secwatch.observer — SEC 8-K summary
======================================

Issuer:     CytomX Therapeutics, Inc. (CTMX)
CIK:        0001501989
Form:       8-K
Filed at:   2023-06-20T23:59:59+00:00
Accession:  0001193125-23-170124
Event type: other
Sentiment:  neutral
Materiality: 0.15
Item codes: 5.07
LLM model:  deepseek-v4-flash:cloud@v2

CytomX Therapeutics stockholders elect directors, ratify auditor, approve say-on-pay at 2023 Annual Meeting
--------------------------------------------------------------------------------

- Matthew P. Young re-elected to board with 23.8M votes for (0.7M against); Elaine V. Jones re-elected with 18.4M for (6.1M against).
- Ratification of Ernst & Young as independent auditor for FY2023 passed with 43.3M for, 0.6M against.
- Non-binding advisory vote on executive compensation approved with 22.1M for, 1.5M against, 0.9M abstain, and 19.3M broker non-votes.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1501989/000119312523170124/0001193125-23-170124-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1501989/000119312523170124/d465222d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-170124

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer